



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)

(Company Registration No. 199908381D)

RECEIPT OF APPROVAL FROM THE SGX-ST IN RELATION TO THE APPLICATION FOR A 3-MONTH PERIOD TO RESTORE THE PUBLIC FLOAT AND CONTINUED TRADING OF THE COMPANY'S SHARES

The Board of Directors of Thomson Medical Group Limited (the "**Company**") refers to its announcement dated 12 September 2023.

The Company had on 13 September 2023 made an application to the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") pursuant to Rule 724(2) of the Listing Manual of the SGX-ST ("**Listing Manual**") to seek approval for a period of 3 months for the public float to be restored and to not suspend trading in the Company's shares on the SGX-ST in the meantime.

The Board is pleased to announce that the Company has today received a letter from SGX-ST advising that it has no objection to:

- (a) granting the Company a period of 3 months until 10 December 2023 to explore options to restore the public float as required under Rule 723 of Listing Manual; and
- (b) the continued trading of the Company's shares during this period.

The approval of the SGX-ST is subject to the Company monitoring the public float and trading activity in its shares on an ongoing basis, and making an immediate request for a trading halt if there is any indication of disorderly trading.

The Company will make such announcements as may be necessary and/or appropriate to update shareholders on the restoration of free float, including but not limited to the completion of the restoration of the free float and/or request for a trading halt in the event of any indication of disorderly trading.

Shareholders and investors are advised to refrain from taking any action, which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group CEO
19 September 2023